IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.
| Revenue (TTM) | $51.57M |
| Gross Profit (TTM) | $18.53M |
| EBITDA | $-2.60M |
| Operating Margin | -8.19% |
| Return on Equity | -73.20% |
| Return on Assets | -5.90% |
| Revenue/Share (TTM) | $2.99 |
| Book Value | $-0.14 |
| Price-to-Book | 331.20 |
| Price-to-Sales (TTM) | 0.22 |
| EV/Revenue | 0.338 |
| EV/EBITDA | -3.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -7.40% |
| Shares Outstanding | $17.56M |
| Float | $10.02M |
| % Insiders | 37.52% |
| % Institutions | 18.66% |
Volatility is currently contracting
SAN JOSE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the third quarter 2026 and provide a business update after the close of trading on November 17, 2026.
Company Expects to Realize Approximately $600,000 in Annualized Cost Savings Company Expects to Realize Approximately $600,000 in Annualized Cost Savings
IRIX's Q2 loss per share widens year over year and revenues decline as Middle East disruptions and reduced sell-through in China weigh on retina sales, offsetting continued growth in the Cyclo G6 product family.
IRIDEX Corporation (IRIX) Q2 2026 Earnings Call Transcript
MOUNTAIN VIEW, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 4, 2026.
MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the second quarter 2026 and provide a business update after the close of trading on August 18, 2026.
MOUNTAIN VIEW, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the expansion of its EyeProGPO product offering to include the Company's line of EndoProbe® Handpieces.
MOUNTAIN VIEW, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming Planet MicroCap Las Vegas 2026 Conference.
IRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 4, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IRIX and any ticker you trade — then tracks every position and per-strategy win rate.
